German researchers have found a molecular switch that determines whether mesenchymal fibroblasts differentiate into fat- or bone-forming cells opening the avenue to modulation of the processes.
Researchers at Roche’s US arms Genentech and Foundation Medicine Inc. (FMI) presented a liquid biopsy test that can be used to identify NSCLC patients who respond to Roche’s PD-L1 blocker Tecentriq earlier than to FMI’s tissue based tumour mutation burden (TMB) assay.
German pharma company and CDMO Boehringer Ingelheim (BI) steps into the lucrative field of gene therapy. Together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), BI aims at developing replacement therapies compensating for mutations that lead to cystic fibrosis.
An investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.
As UK’s departure from the EU is fast approaching, stakeholders are preparing for the disruption a hard Brexit might cause. While EMA is scaling back activities, pharma companies are stockpiling meds.
Antiviral drug discovery company ReViral announced the successful completion of a of a US$55m Series B financing. The funding will go toward clinical studies for its respiratory tract infection treatment.
The global market value of biodegradable plastics has passed the US$1.1bn mark in 2018, a report by IHS Markit says. More than half of the demand comes from Western Europe, driven by increasing regulation.
Swiss pharma giant Novartis announced that its monoclonal antibody for migraine prevention Aimovig (erenumab) has received market approval in the EU. It is the first treatment of its kind to be available here.
A financing agreement with the European Investment Bank will allow the French cancer specialist Nanobiotix to borrow up to €40m through loan – money the company needs to boost its research, development and innovation activities.
The EU Court of Justice has ruled that plants created using novel genome editing methods will be classed as genetically modified organisms and therefore have to follow the strict EU guidelines for GMOs.